304 related articles for article (PubMed ID: 28624108)
21. A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients.
Lim WH; Eris J; Kanellis J; Pussell B; Wiid Z; Witcombe D; Russ GR
Am J Transplant; 2014 Sep; 14(9):2106-19. PubMed ID: 25088685
[TBL] [Abstract][Full Text] [Related]
22. Use of Everolimus in Liver Transplantation: Recommendations From a Working Group.
De Simone P; Fagiuoli S; Cescon M; De Carlis L; Tisone G; Volpes R; Cillo U;
Transplantation; 2017 Feb; 101(2):239-251. PubMed ID: 27495768
[TBL] [Abstract][Full Text] [Related]
23. Calcineurin-inhibitor-sparing immunosuppressive protocols.
Bestard O; Cruzado JM; Grinyó JM
Transplant Proc; 2005 Nov; 37(9):3729-32. PubMed ID: 16386520
[TBL] [Abstract][Full Text] [Related]
24. The Role of mTOR Inhibitors after Liver Transplantation for Hepatocellular Carcinoma.
Todeschini L; Cristin L; Martinino A; Mattia A; Agnes S; Giovinazzo F
Curr Oncol; 2023 Jun; 30(6):5574-5592. PubMed ID: 37366904
[TBL] [Abstract][Full Text] [Related]
25. Renal function in heart transplant patients after switch to combined mammalian target of rapamycin inhibitor and calcineurin inhibitor therapy.
Helmschrott M; Rivinius R; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2017; 11():1673-1680. PubMed ID: 28652705
[TBL] [Abstract][Full Text] [Related]
26. Basiliximab with delayed introduction of calcineurin inhibitors as a renal-sparing protocol following liver transplantation in children with renal impairment.
Mouzaki M; Yap J; Avinashi V; Babu A; Fu A; Deangelis M; Van Roestel K; Ghanekar A; Kamath B; Avitzur Y; Fecteau A; Jones N; Ling S; Grant D; Ng V
Pediatr Transplant; 2013 Dec; 17(8):751-6. PubMed ID: 24118898
[TBL] [Abstract][Full Text] [Related]
27. The Effect of Mammalian Target of Rapamycin Versus Calcineurin Inhibitor-based Immunosuppression on Measured Versus Estimated Glomerular Filtration Rate After Orthotopic Liver Transplantation.
Zitta S; Schaffellner S; Gutschi J; Meinitzer A; Kniepeiss D; Artinger K; Reibnegger G; Rosenkranz AR; Wagner D
Transplantation; 2015 Jun; 99(6):1250-6. PubMed ID: 25606796
[TBL] [Abstract][Full Text] [Related]
28. CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality.
Rabot N; Büchler M; Foucher Y; Moreau A; Debiais C; Machet MC; Kessler M; Morelon E; Thierry A; Legendre C; Rivalan J; Kamar N; Dantal J
Transpl Int; 2014 Sep; 27(9):956-65. PubMed ID: 24964147
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the immunosuppressive regimen in heart transplantation.
Eisen H; Ross H
J Heart Lung Transplant; 2004 May; 23(5 Suppl):S207-13. PubMed ID: 15093807
[TBL] [Abstract][Full Text] [Related]
30. Immunosuppressive Drugs in Liver Transplant: An Insight.
Panackel C; Mathew JF; Fawas N M; Jacob M
J Clin Exp Hepatol; 2022; 12(6):1557-1571. PubMed ID: 36340316
[TBL] [Abstract][Full Text] [Related]
31. Immunosuppression Modification by Everolimus With Minimization of Calcineurin Inhibitors Recovers Kidney Graft Function Even in Patients With Very Late Conversion and Also With Poor Graft Function.
Nojima M; Yamada Y; Higuchi Y; Shimatani K; Kanematsu A; Yamamoto S
Transplant Proc; 2017; 49(1):41-44. PubMed ID: 28104155
[TBL] [Abstract][Full Text] [Related]
32. Prospective study of everolimus with calcineurin inhibitor-free immunosuppression after heart transplantation: results at four years.
Engelen MA; Welp HA; Gunia S; Amler S; Klarner MP; Dell'aquila AM; Stypmann J
Ann Thorac Surg; 2014 Mar; 97(3):888-93. PubMed ID: 24206966
[TBL] [Abstract][Full Text] [Related]
33. Conversion from calcineurin inhibitor-based immunosuppression to mammalian target of rapamycin inhibitors or belatacept in renal transplant recipients.
Mulgaonkar S; Kaufman DB
Clin Transplant; 2014 Nov; 28(11):1209-24. PubMed ID: 25142257
[TBL] [Abstract][Full Text] [Related]
34. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
35. Strategies to prevent or reduce acute and chronic kidney injury in liver transplantation.
Saner FH; Cicinnati VR; Sotiropoulos G; Beckebaum S
Liver Int; 2012 Feb; 32(2):179-88. PubMed ID: 21745304
[TBL] [Abstract][Full Text] [Related]
36. Everolimus with early withdrawal or reduced-dose calcineurin inhibitors improves renal function in liver transplant recipients: A systematic review and meta-analysis.
Lin M; Mittal S; Sahebjam F; Rana A; Sood GK
Clin Transplant; 2017 Feb; 31(2):. PubMed ID: 27862340
[TBL] [Abstract][Full Text] [Related]
37. Calcineurin inhibitor minimization protocols in liver transplantation.
Farkas SA; Schnitzbauer AA; Kirchner G; Obed A; Banas B; Schlitt HJ
Transpl Int; 2009 Jan; 22(1):49-60. PubMed ID: 19121146
[TBL] [Abstract][Full Text] [Related]
38. Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment: Results of a Pilot Study (PATRON07).
Schnitzbauer AA; Sothmann J; Baier L; Bein T; Geissler EK; Scherer MN; Schlitt HJ
Transplantation; 2015 Dec; 99(12):2565-75. PubMed ID: 26018348
[TBL] [Abstract][Full Text] [Related]
39. Calcineurin inhibitor- and corticosteroid-free immunosuppression in pediatric heart transplant patients.
Sierra CM; Tan R; Eguchi J; Bailey L; Chinnock RE
Pediatr Transplant; 2017 Feb; 21(1):. PubMed ID: 27658616
[TBL] [Abstract][Full Text] [Related]
40. Impact of combined mycophenolate mofetil and low-dose calcineurin inhibitor therapy on renal function, cardiovascular risk factors, and graft function in liver transplant patients: preliminary results of an open prospective study.
Beckebaum S; Cicinnati VR; Klein CG; Brokalaki E; Yu Z; Malago M; Frilling A; Gerken G; Broelsch CE
Transplant Proc; 2004 Nov; 36(9):2671-4. PubMed ID: 15621120
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
